La Fondazione LIRH onlus promuove ogni anno iniziative di informazione e divulgazione. Di seguito troverai elencate tutte le nostre iniziative.
27/1/2021
A recent study identifies a new biochemical mediator potentially able to represent a marker of neurodegeneration in Huntington's disease, Alzheimer's disease and Parkinson's disease.
20/01/2021
The first two Italian patients started the trial today, January 20, 2021, in Rome, at the CSS-Mendel Institute, section of IRCCS Casa Sollievo della Sofferenza and Coordinating Center for Italy, under the guidance of Principal Investigator Prof. Ferdinando Squitieri.
07/12/2020
This is the title of LIRH FoundationAnnual Conference, which will take place online on Saturday 12 December from 10.00 to 13.00 am (CEST)
Also this year, on time like every other year, we will provide a comprehensive overview of the main clinical trials on Huntington's disease; a rare disease still lacking of a definitive cure, but towards which interest is strongly growing on the part of both researchers and the pharmaceutical industry.
3/12/2020
Hey you, yes you, can you read the text?
... try turning the screen and reading it from another perspective.
Good, now we are already on the right track.
24/11/2020
In an official statement of 17 November 2020, PTC Therapeutics announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. The Phase 1 study includes both single and multiple ascending dosing regimens that will help establish the safety, pharmacology, and dose selection for the Phase 2 study.
13/11/2020
A recent study published in “Experimental Brain Research”, a journal of the Nature Group, investigates the relationship between the ability to visually scan and the difficulty of recognizing others’ emotions, in the pre-symptomatic phase of Huntington's disease (preHD). Why is this important?
29/10/2020
On October 28th, in an official press release, Prilenia Therapeutics , a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announced the enrollment of the first patients in the U.S. into PROOF-HD, a global phase 3 clinical trial for Huntington’s Disease (HD).
23/10/2020
14/10/2020
25/09/2020
The SIGNAL trial began in 2015 in 20 centers across the United States, involving 301 patients with Huntington's disease in the early stages or not yet symptomatic .
The study was designed to test whether a drug called pepinemab(also known as VX15) produced by Vaccinex, was safe for people with HD, and whether it could slow the effects of HD, like changes to the brain, and difficulties with thinking, movements, and behavior.
